Interview: Jihad Massoud, CEO of Massoud Pharma Group, on improving logistics and procurement, and reopening banking channels

How would you assess Syria’s pharmaceutical manufacturing capacity?

JIHAD MASSOUD: Even before the crisis, pharmaceuticals were a strategically important sector in Syria. The country had 30-40 manufacturing facilities supplying not only the domestic market but exporting across the region, including to Iraq, Sudan and Yemen. Syrian pharmaceuticals were respected for the breadth of products and relatively strict quality controls, with the Ministry of Health monitoring finished products at wholesalers and pharmacies through regular random sampling. The structure of the market, however, has since shifted. There are approximately 80 licensed manufacturing facilities operating, which is not sustainable under current conditions. The issue is less about technical capability and more about market saturation. With so many producers, competition is intense, margins are thin and survival has become a priority over profitability.

To what extent does the regulatory framework shape quality standards and market access?

MASSOUD: Regulation has become more demanding in recent years, which is a positive development. Although approvals slowed in 2025, regulators have continued quality control activities, including factory inspections. There is now a clear intention to raise technical requirements across the sector. What manufacturers would like to see now is stronger institutional capacity rather than relaxed oversight. Higher standards will inevitably mean that some companies do not survive, but that consolidation could improve overall quality and credibility.

Which role do local pharmaceutical manufacturers play in reducing import dependence?

MASSOUD: Syrian pharmaceutical manufacturers have played a key role in reducing import dependence across mainstream therapeutic categories, covering the most common chronic and acute conditions. The categories that remain import-dependent, such as plasma derivatives, vaccines and most oncology treatments, reflect global manufacturing realities rather than any failure of local industry. What local production provides that imports cannot is supply continuity. The challenge now is making up for lost ground. A decade of crisis cost the sector in investment, technology and regulatory standards, and catching up with regional peers requires serious commitment to upgrading manufacturing facilities and building technical and regulatory capability. That is the investment the industry needs to make.

In what ways do pricing controls and affordability considerations affect long-term sustainability?

MASSOUD: Pricing remains one of the most challenging constraints. Locally manufactured medicines are treated as basic necessities and are priced by the government. Although prices have increased, they have not reflected the full impact of currency devaluation. As a result, locally produced medicines are substantially cheaper than imported alternatives. That flexibility is being reviewed and how import pricing is set will be one of the defining commercial questions for the sector. While price controls protect affordability, they also limit manufacturers’ ability to reinvest and modernise.

What is the long-term outlook for exports?

MASSOUD: Export potential has been heavily affected by both internal and external factors. Many traditional markets, such as Libya and Yemen, face ongoing instability, while others like Iraq have developed their own manufacturing capacity. Internally, conditions are more secure than before, which addresses part of the problem. As logistics improve and banking channels reopen following the easing of sanctions, Syrian manufacturers could regain competitiveness in selected markets. As the market opens further from 2027, competition will intensify and human capital will become more critical. However, the opportunity will likely be gradual and selective, rather than a return to past export volumes.